An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics
Open Access
- 22 May 2015
- journal article
- special populations
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 55 (12), 1395-1405
- https://doi.org/10.1002/jcph.550
Abstract
Edoxaban, a once-daily, oral, direct factor Xa inhibitor, is approved for stroke prevention in nonvalvular atrial fibrillation and venous thromboembolism treatment. This study examined the effects of mild or moderate hepatic impairment on the pharmacokinetics of edoxaban and its metabolite M4. Thirty-three subjects enrolled in 4 treatment cohorts—mild hepatic impairment (n = 8), moderate hepatic impairment (n = 9), and 2 cohorts of healthy controls matched for age, sex, and weight (each n = 8)—and received a single 15-mg dose of edoxaban. Plasma pharmacokinetics for edoxaban and M4, prothrombin time (PT), activated partial thromboplastin time (aPTT), and safety data were measured over 72 hours. Edoxaban and M4 exposures were similar in subjects with mild or moderate hepatic impairment compared with matched controls. Higher PT and aPTT values were observed at baseline and after edoxaban dosing in the hepatic impairment groups compared with healthy controls. Edoxaban 15 mg was well tolerated in all cohorts. These results suggest that edoxaban exposure does not significantly increase in patients with mild or moderate hepatic impairment. However, because of the potential for underlying coagulopathy, edoxaban is not recommended for use in patients with moderate or severe hepatic impairment. No dose reduction is recommended for patients with mild hepatic impairment.This publication has 31 references indexed in Scilit:
- Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa InhibitorAmerican Journal of Cardiovascular Drugs, 2013
- Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationThrombosis and Haemostasis, 2012
- The Coagulopathy of Chronic Liver DiseaseNew England Journal of Medicine, 2011
- Epidemiology and Risk Factors for Venous ThrombosisSeminars in Hematology, 2007
- Predictive Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Estimating Renal FunctionJournal of the American Society of Nephrology, 2005
- Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation testsHepatology, 2005
- Coagulation disorders in patients with cirrhosis and severe sepsisLiver International, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973